Merged Publicis-Omnicom may speak with American accent
PARIS (Reuters) – The advertising giant to be formed from the merger of Publicis and Omnicom may resolve any clash between its French and U.S. arms by taking on a more American identity, some industry observers said on Monday.
BMW targets “meaningful” sales with electric i-series
LONDON (Reuters) – BMW is targeting a “meaningful” chunk of the electric-car market and expects demand to be driven up as urban populations rise, its sales chief said on Monday as he unveiled the company’s battery-powered i3 model.
Judge says Bernanke should testify in AIG bailout lawsuit
(Reuters) – A U.S. judge ruled on Monday that Federal Reserve Chairman Ben Bernanke should testify in the multibillion-dollar lawsuit by the former chief of American International Group Inc , Maurice “Hank” Greenberg, against the United States over the…
Pending home sales pull back in June as rates rise
WASHINGTON (Reuters) – Contracts to purchase previously owned U.S. homes fell in June, retreating from a more than six-year high and suggesting rising mortgage rates were starting to dampen home sales.
Publicis, Omnicom say major clients welcome merger
PARIS (Reuters) – The chief executives of Publicis and Omnicom said they had spoken to major clients about their planned merger and did not anticipate major problems with big advertisers defecting to rivals in the transition period.
France wants mandate for EU-US trade talks published
PARIS (Reuters) – France called on Monday for the European Commission to make public its mandate to negotiate EU-U.S. free-trade talks, citing what it said was an atmosphere of mistrust over efforts to forge a landmark pact.
Drugmaker Perrigo to buy Ireland’s Elan for $8.6 billion
DUBLIN (Reuters) – U.S. drugmaker Perrigo agreed to buy Elan for $8.6 billion in a deal that will hand it tax savings from being domiciled in Ireland and royalties from a blockbuster multiple sclerosis treatment.
Pfizer to internally split generic, branded drugs operations
(Reuters) – Pfizer Inc on Monday said it plans to internally separate its commercial operations into three business segments, including two units that sell patent-protected branded drugs and one that sells generic medicines.
Analysis: Bayer immune to pharma’s breakup bug?
FRANKFURT (Reuters) – Investors banking on Bayer to embrace a trend in the pharma sector to split off non-core units may be too far ahead of the curve.
Bankers could lose part of bonus under EU watchdog proposal
LONDON (Reuters) – Bankers could see part of their bonus wiped out if their employer’s capital position falls below certain levels, according to a proposal from the European Union’s banking regulator aimed at protecting taxpayers.
